-
Cubans bid farewell to revolution hero Valdes
-
Morocco squad 'supporting' Hakimi despite impending rape trial
-
Ronaldo delights in silencing 'attacks' after making World Cup history
-
Airbus to inspect 16 A380s after cracks found on plane wings
-
'Paris in this heat is awful': Tourists change plans as sites close early
-
Bolivian government says cleared all protest roadblocks
-
'I'm back': Ronaldo scores at sixth World Cup as Portugal run riot
-
France has hottest-ever day as 'unbearable' heatwave keeps scorching Europe
-
US TV news host begs for info after kidnap note says mother is dead
-
Ronaldo double fires Portugal, England eye last 32
-
Ronaldo scores at sixth World Cup as Portugal run riot
-
Hollywood powerhouses bring AI fight to Europe
-
Portugal's Ronaldo first man to score at six World Cups
-
What is driving Europe's heatwave?
-
Rubio says US will not accept Iranian tolls on Hormuz
-
Spain's Oyarzabal happy to play through pain at World Cup
-
Marco Rubio in Gulf to reassure allies hit hard by Mideast war
-
US Supreme Court rules against man whose dreadlocks were cut off in prison
-
American Michele Kang agrees deal to buy French club Lyon
-
UN to begin evacuating stranded Mideast sailors after US-Iran talks
-
French farmers suffer arid crops, heat-stricken animals
-
Tech drags down world stocks, oil dips on supply hopes
-
Scorching heat shuts Paris landmarks early as France swelters
-
Shootout traps tourists at Rio sunrise lookout
-
Ipswich hire Gary O'Neil as manager
-
Heatwave sparks health warnings across Europe
-
Lake wins Wales captaincy race ahead of Morgan
-
Hundreds of schools close as UK braces for record-breaking heatwave
-
Tech names drag down world stocks, oil dips on supply hopes
-
Starmer vows 'orderly' transition as Labour MPs mull bid to be PM
-
Reports of Dupont inclusion in France squad 'bordering on annoying' says Galthie
-
ACTIVIST SHAREHOLDER FILES SCHEDULE 13D IN EQUUS TOTAL RETURN, INC.
-
England coach McCullum denies rift with 'good friend' Stokes
-
Europe: the world's fastest-warming continent
-
Taliban officials hold EU migration talks in Brussels
-
Gennaro Gattuso returns to coaching with Lazio after Italy debacle
-
Kenya halts US Ebola facility: health minister tells court
-
Why the heat is wreaking havoc on Europe's trains
-
Zelensky to skip key Ukraine conference in Poland over WWII row
-
Seoul leads rout for tech shares as oil prices dip
-
Europe heatwave closes schools, threatens health
-
India monsoon sweeps north but brings less rain than usual
-
Germany eyes longer working lives in pension reform plan
-
UK and markets await Burnham's economic plans
-
Iran says won't allow UN inspectors at bombed nuclear sites
-
Heineken names new CEO after predecessor's shock departure
-
Banned Vondrousova insists she has 'never doped'
-
Schools plan to close as UK braces for record-breaking heatwave
-
UN chief urges AI firms to 'come clean' over environmental footprint
-
India startup head Kunal Shah appointed as new WhatsApp boss
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
F.Wilson--AT